Sanofi (SNY)
| Market Cap | 116.24B |
| Revenue (ttm) | 53.71B |
| Net Income (ttm) | 10.72B |
| Shares Out | 1.22B |
| EPS (ttm) | 8.65 |
| PE Ratio | 5.64 |
| Forward PE | 10.18 |
| Dividend | $1.60 (3.28%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 1,078,568 |
| Open | 48.53 |
| Previous Close | 48.05 |
| Day's Range | 48.47 - 48.90 |
| 52-Week Range | 44.73 - 60.12 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 65.00 (+33.25%) |
| Earnings Date | Jul 31, 2025 |
About X
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $65.0, which is an increase of 33.25% from the latest price.
News
Sanofi stops supply of high cholesterol drug to China due to limited availability
Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French pharmaceuticals firm and its partner Regeneron Pharmaceuticals, in China due to lim...
Sanofi: Playing To Win
Sanofi's strategic pivot to immunology and rare diseases, plus AI-driven R&D, targets higher margins and sustainable long-term growth. Blockbuster drugs like Dupixent, Altuviiio, and Beyfortus, alongs...
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”).
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
European drugmakers fall after Trump raises stakes over US drug price cuts
Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...
Sanofi (SNY) Q2 2025 Earnings Call Transcript
Sanofi (NASDAQ:SNY) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care François-Xavier Roger - Executive VP & CFO Houma...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Press release: Online availability of Sanofi's half-year financial report for 2025
Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and ...
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
Sanofi SA SNY reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.
Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.
Sanofi revises annual sales growth expectations on strong Dupixent demand
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer tr...
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range.
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment...
U.S. and European Union trade deal could cost the pharma industry up to $19 billion
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said ...
Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
France's Sanofi to acquire biotech firm Vicebio for $1.15 bln
French pharmaceuticals company Sanofi said on Tuesday it agreed to acquire British private biotechnology firm Vicebio for a total of $1.15 billion, in a bid to expand its respiratory vaccines portfoli...
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held bi...
Press Release: Sanofi completes acquisition of Blueprint Medicines
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfol...
Thermo Fisher acquires Sanofi's New Jersey manufacturing site
Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical medicines for the French drugmaker.